by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : February 2005
product news ethical products Reducing violent behaviour L ONG-TERM treatment with Zyprexa (olanzapine) significantly lowered the risk of violent behaviour in people with schizophrenia versus risperidone (Risperdal, Janssen) according to a recent study published in the December issue of the Journal of Clinical Psychiatry. In this three-year naturalistic or ‘real world’ study, the Schizophrenia Care and Assessment Program (SCAP), improved medication adherence was shown to be an important element that contributed to the reduced violence risk in patients treated with Zyprexa. ‘Violent behaviour, even in a small proportion of people with schizophrenia, can stigmatise all those with the disease, preventing acceptance of people with psychiatric disabilities in society, disrupting continuity of care, and limiting the effectiveness of community- based mental health services,’ said Dr Jeff Swanson, Associate Professor of Psychiatry and Behavioral Sciences at Duke University Medical Centre and SCAP investigator. Unlike a traditional clinical trial, SCAP is a longitudinal obser- vational study designed to understand the treatment provided to schizophrenia patients in community care settings. SCAP is one of the largest naturalistic studies ever conducted in the US, consisting of 2,400 patients treated at centres across the country. SCAP investigators from Duke University Medical Centre studied violent behaviour in a smaller group of patients in North Carolina, one of the six states where SCAP was carried out. Rates of violence among people who were initiated on Zyprexa were compared with people who were initiated on risperidone at six-month intervals. Remaining on Zyprexa for one year or more significantly lowered the risk of violent behaviour. No significant change in violence risk was found for subjects remaining on risperidone for one year or more. ¦ Risk of onset microalbuminuria reduced T REATMENT with either the ACE inhibitor trandolapril (Gopten), alone or in combination with the non- dihydropyridine calcium-channel blocker verapamil (Isoptin), significantly reduces the incidence of microalbuminuria in normoalbuminuric hypertensive, type 2 diabetic patients, according to new findings published this month in The New England Journal of Medicine. The first large-scale trial of normoalbuminuria patients to evaluate ERZONE will no longer be supplied in Australia, unless specific approval is given for individual patients by the Serzone discontinued S Lantus autopen available A VENTIS Pharma has introduced the Autopen 24, an automatic insulin delivery pen by Owen Mumford, for Lantus (insulin glargine) 3 mL cartridges. Lantus is a human insulin analogue with peakless, 24-hour activity and once- a-day dosing. It is indicated for the treatment of Type 1 diabetes mellitus in adults and children, and Type 2 diabetes in adults who require insulin for the control of hyperglycaemia and is available on private prescription. The Autopen 24, with one or two unit dosing increments, is available free of charge to patients prescribed Lantus from endocrinologists and diabetes educators. ¦ Risperdal PBS approved R ISPERDAL Consta, the first long- acting, atypical antipsychotic injection, is available on the PBS (Authority Required) from 1 February 2005, for the treatment of schizophrenia. This new product is hoped to benefit patients who are non-adherent to, partially adherent to, or who have tolerability issues with their current antipsychotic medication. According to the manufacturer, the possibility of preventing the onset of persistent microalbuminuria, BENEDICT (Bergamo Nephrologic Diabetes Complications Trial) was a multi-centre, double-blind, placebo-controlled, randomised trial of 1,204 patients for at least three years. The study showed that the likelihood of developing persistent microalbuminuria could be reduced by more than 40 per cent in normoalbuminuric hypertensive type 2 diabetic patients. ¦ Therapeutic Goods Administration, following a request by manufacturer Bristol-Myers Squibb to have the drug removed from the Australian Register of 100 ? THE AUSTRALIAN JOURNAL OF PHARMACY VOL 86 FEBRUARY 2005 Janssen-Cilag, Risperdal Consta combines the benefits of continuous delivery with broad efficacy and a low level of adverse events. Treatment with Risperdal Consta is associated with decreased rehospitalisation rates and improved quality of life in patients with schizophrenia. ¦ Therapeutic Goods. In January 2004, Bristol-Myers Squibb advised health professionals that it would cease selling Serzone tablets at the end of April 2004.¦